TY  - GEN
AU  - Muñoz, Miguel
AU  - Parrilla, Julio
AU  - Rosso, Marisa
AU  - Coveñas, Rafael
PY  - 2019
DO  - 10.2340/00015555-3148
UR  - http://hdl.handle.net/10668/13534
T2  - Acta dermato-venereologica
AB  - A recently published study of 8 patients with cutaneous T-cell lymphomas (CTCL) treated with aprepitant (1) reported that the neurokinin-1 receptor (NK-1R) antago-nist aprepitant did not completely modify CTCL disease activity. The authors concluded...
LA  - en
PB  - Medical Journals Sweden AB
KW  - Antineoplastic Agents
KW  - Dose-Response Relationship, Drug
KW  - Lymphoma, T-Cell, Cutaneous
KW  - Skin Neoplasms
KW  - Treatment Outcome
KW  - Antipruritics
KW  - Aprepitant
KW  - Drug Administration Schedule
KW  - Humans
KW  - Neurokinin-1 Receptor Antagonists
KW  - Pruritus
TI  - Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
TY  - letter
VL  - 99
ER  -